MGX · XBRL financial data

Metagenomi Therapeutics financial statements, every quarter

The same tables from 10 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (MGX's year ends in late December)

In thousands of dollars	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	11,159	20,008	11,514	9,614*	4,127	8,513	8,659	3,911*	1,248	—
Research and development	31,439	28,320	26,256	23,164*	25,142	22,507	25,283	21,501*	19,300	22,512
General and administrative	8,752	8,551	7,641	7,073*	6,805	6,993	6,215	6,777*	6,535	6,004
Total operating expenses	40,191	36,871	33,897	30,237*	31,947	29,500	31,498	28,278*	25,835	28,516
Operating income (loss)	(29,032)	(16,863)	(22,383)	(20,623)*	(27,820)	(20,987)	(22,839)	(24,367)*	(24,587)	(28,773)
Interest income	3,934	3,976	3,616	3,196*	2,887	2,485	2,214	1,884*	1,539	1,256
Other income (expense)	(50)	(51)	(57)	(49)*	(8)	(70)	(2)	(11)*	(1)	35
Income tax expense (benefit)	0	(2,199)	(2,106)	(1,208)*	98	44	(234)	34*	10	0
Net income (loss)	(25,148)	(10,739)	(18,773)	(23,398)*	(25,039)	(19,908)	(20,393)	(22,528)*	(23,059)	(27,482)
Earnings per share, basic USD per share	(1.19)	(0.29)	(0.51)	—	(0.68)	(0.54)	(0.55)	(0.60)*	(0.61)	(0.73)
Earnings per share, diluted USD per share	(1.19)	(0.29)	(0.51)	—	(0.68)	(0.54)	(0.55)	(0.60)*	(0.61)	(0.73)
Weighted average shares, basic thousands of shares	21,138	36,625	36,766	37,492*	37,019	37,157	37,349	37,473*	37,581	37,658
Weighted average shares, diluted thousands of shares	21,138	36,625	36,766	37,492*	37,019	37,157	37,349	37,473*	37,581	37,658

Balance sheet

CSV

Fiscal quarters (MGX's year ends in late December)

In thousands of dollars	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	102,558	61,181	25,117	27,386	29,195	26,850	32,773	41,722	25,306	39,028
Marketable securities	224,847	238,740	249,470	220,921	196,775	178,143	151,341	119,077	114,856	81,636
Accounts receivable	—	—	—	1,100	900	900	—	305	0	0
Prepaid and other current assets	6,156	6,010	7,117	8,396	6,213	5,815	4,746	4,434	4,396	3,804
Total current assets	335,643	307,579	282,293	257,960	233,195	211,681	189,820	165,538	144,558	124,468
Property and equipment, net	20,960	20,711	19,719	17,740	16,521	15,113	13,895	12,288	11,160	9,896
Right-of-use asset	42,497	41,359	40,191	39,917	38,674	37,283	36,011	35,094	33,761	31,772
Total assets	415,403	385,905	358,348	324,599	297,866	272,284	247,937	221,103	196,953	173,701
Accounts payable	6,843	3,453	3,103	533	2,670	2,891	1,215	1,489	2,398	2,603
Total current liabilities	70,701	52,810	45,692	37,309	39,893	33,265	29,583	22,933	22,499	27,632
Lease liability, non-current	43,680	42,545	41,377	40,186	38,834	37,482	36,092	34,632	33,081	31,485
Total liabilities	139,770	116,486	102,575	89,742	85,208	76,453	69,490	62,507	59,168	61,134
Accumulated deficit	(170,092)	(180,831)	(199,604)	(223,002)	(248,041)	(267,949)	(288,342)	(310,870)	(333,929)	(361,411)
Total stockholders' equity	275,633	269,419	255,773	234,857	212,658	195,831	178,447	158,596	137,785	112,567
Total liabilities and equity	415,403	385,905	358,348	324,599	297,866	272,284	247,937	221,103	196,953	173,701
Common shares outstanding (cover page) thousands of shares	37,464	37,429	37,424	37,383	37,381	37,533	≈0	37,621	37,647	37,777

≈ Rounded on cover: the filing states this count rounded, and it sits more than 1% off the weighted shares for the period.

Cash flows

CSV

Fiscal quarters (MGX's year ends in late December)

In thousands of dollars	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(25,148)	(10,739)	(18,773)	(23,398)*	(25,039)	(19,908)	(20,393)	(22,528)*	(23,059)	(27,482)
Stock-based compensation	5,057	4,512*	3,223*	3,412*	2,928	3,221*	3,010*	2,694*	2,552	2,268*
Net cash from operating activities	(29,850)	(26,309)*	(26,638)*	(26,276)*	(22,842)	(21,251)*	(21,253)*	(23,546)*	(21,175)	(19,513)*
Purchases of property and equipment	915	665*	1,200*	334*	288	127*	74*	85*	25	125*
Net cash from investing activities	(94,732)	(13,036)*	(8,934)*	28,545*	24,728	19,072*	27,363*	32,366*	3,986	33,168*
Net cash from financing activities	86,537	(2,032)*	(492)*	0*	(77)	(166)*	(187)*	74*	(27)	67*
Net change in cash	(38,045)	(41,377)*	(36,064)*	2,269*	1,809	(2,345)*	5,923*	8,894*	(17,216)	13,722*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Metagenomi Therapeutics	39,028	not reported	(19,513)*	37.8M	6.2 quarters	Q2 FY26 10-QJun 30, 2026
Fitlife Brands	1,089	not reported	3,635*	9.4M	—	Q2 FY26 10-QJun 30, 2026
Immucell	8,860	7,186	3,019*	9.1M	—	Q2 FY26 10-QJun 30, 2026
Cue Biopharma	17,392	7,877	(29,004)*	7.3M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Avalo Therapeutics	64,988	not reported	(11,541)*	57.8M	23.9 quarters	Q3 FY26 10-QSep 30, 2026
Precision Biosciences	81,698	0	(15,132)*	27.9M	6.1 quarters	Q3 FY26 10-QSep 30, 2026
Opus Genetics	88,812	755	(11,950)*	83.2M	7.4 quarters	Q2 FY26 10-QJun 30, 2026
Acumen Pharmaceuticals	53,075	not reported	(26,653)*	72.3M	3.4 quarters	Q3 FY26 10-QSep 30, 2026
iBio	56,395	0*	(6,228)*	64.3M	14.1 quarters	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 2:09 PM ET. The filing on SEC.gov is the record.